Brainstorm Cell Therapeutics announces results of Phase 2 study of NurOwn® in Patients with Amyotrophic Lateral Sclerosis (ALS).

19 Jul 2016

Brainstorm develops adult stem cell therapies derived from autologous bone marrow cells for the treatment of neurodegenerative diseases.  Results of a Phase 2 study announced on 18 July 2016 demonstrated that NurOwn was safe and well tolerated.  It was also reported to achieve secondary efficacy endpoints indicating evidence of clinical benefit in a 24 week study.  

Back to main news